STON2

Across TCGA pan-cancer cohorts, STON2 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated STON2 data layer compared with 6 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher STON2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated STON2 expression acts as an unfavorable survival marker, although some lineages such as LUSC and KIRP show a favorable association.

STAD, LUSC, and KIRP are the cancer types where STON2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Quartile	All	0.217	0.479	<.001	70	view →
LUSC	DFS	Quartile	II,III,IV	0.684	0.428	.002	63	view →
KIRP	DFS	Quartile	II,III,IV	1.000	0.554	<.001	50	view →
HNSC	OS	Median	IV	0.140	0.431	<.001	45	view →
BRCA	OS	Median	All	0.944	0.903	.001	44	view →
KIRC	DFS	Quartile	IV	0.810	0.387	.004	30	view →
ACC	OS	Quartile	II,III,IV	0.545	1.000	.003	29	view →
UCEC	OS	Quartile	All	0.415	0.829	.004	18	view →
CHOL	OS	Median	All	0.308	0.876	.006	18	view →
UCS	DFS	Tertile	All	0.389	0.700	.010	16	view →
UVM	DFS	Median	II,III,IV	0.343	0.589	.027	16	view →
READ	DFS	Median	III,IV	0.599	0.905	.010	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

STON2–STAD (DFS)

Open the STAD breakdown →